EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Guideline-Directed Medical Therapy in Severe Heart Failure with Reduced Ejection Fraction: An Analysis from the HELP-HF Registry

Leitliniengerechte medikamentöse Therapie bei schwerer Herzinsuffizienz mit reduzierter Ejektionsfraktion: Analyse aus dem HELP-HF-Register

Daniela Tomasoni, Matteo Pagnesi, Giada Colombo, Mauro Chiarito, Davide Stolfo, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Giuseppe Maggi, Riccardo Maria Inciardi, Ferdinando Loiacono, Marta Maccallini und 14 weitere

European Journal of Heart Failure · 01.02.2024 · 26 (2) · 327-337

DOI: 10.1002/ejhf.3081 ↗

Auf einen Blick

Bei 699 Patient:innen mit schwerer HFrEF und mindestens einem „I NEED HELP“-Marker war die GDMT oft unvollständig und unterdosiert. BB und ACEi/ARB/ARNI waren mit weniger Tod oder HF-Hospitalisationen verbunden.

Fragestellung

Wie häufig werden GDMT-Medikamente bei schwerer HFrEF eingesetzt und welche prognostische Bedeutung haben sie im Alltag?

Methode

Multizentrisches Register mit 699 konsekutiven Patient:innen mit HFrEF und mindestens einem „I NEED HELP“-Marker.

Ergebnisse

BB erhielten 574 (82%) Patient:innen, ACEi/ARB/ARNI 381 (55%) und MRA 416 (60%). ≥50% der Zieldosis erreichten 41%, 22% und 56%. BB: aHR 0,63 (95 %-KI 0,48–0,84); ACEi/ARB/ARNI: aHR 0,74 (95 %-KI 0,58–0,95).

Schlussfolgerung der Autor:innen

Bei schwerer HFrEF blieben Verordnung und Aufdosierung der GDMT begrenzt. Ein relevanter Anteil war aus unbekannten Gründen unterbehandelt; BB und ACEi/ARB/ARNI waren mit geringerer Mortalität/Morbidität assoziiert.

Kernaussagen

  • BB: 574/699; ≥50% der Zieldosis bei 41%
  • ACEi/ARB/ARNI: 381/699; ≥50% der Zieldosis bei 22%
  • BB und ACEi/ARB/ARNI mit weniger Tod oder HF-Hospitalisationen assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Heart Failure, online erschienen am 22.11.2023. Verfasst von Daniela Tomasoni und 25 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical specialties, Radiological Sciences and Public Health, University of …. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Persistent symptoms despite guideline-directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks of patients with advanced heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data on GDMT use, dose, and prognostic implications are lacking. Methods and results We included 699 consecutive patients with HFrEF and at least one ‘I NEED HELP’ marker for advanced HF enrolled in a multicentre registry. Beta-blockers (BB) were administered to 574 (82%) patients, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or angiotensin receptor–neprilysin inhibitors (ACEi/ARB/ARNI) were administered to 381 (55%) patients and 416 (60%) received mineralocorticoid receptor antagonists (MRA). Overall, ≥50% of target doses were reached in 41%, 22%, and 56% of the patients on BB, ACEi/ARB/ARNI and MRA, respectively. Hypotension, bradycardia, kidney dysfunction and hyperkalaemia were the main causes of underprescription and/or underdosing, but up to a half of the patients did not receive target doses for unknown causes (51%, 41%, and 55% for BB, ACEi/ARB/ARNI and MRA, respectively). The proportions of patients receiving BB and ACEi/ARB/ARNI were lower among those fulfilling the 2018 HFA-ESC criteria for advanced HF. Treatment with BB and ACEi/ARB/ARNI were associated with a lower risk of death or HF hospitalizations (adjusted hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.48–0.84, and HR 0.74, 95% CI 0.58–0.95, respectively).

Conclusions

In a large, real-world, contemporary cohort of patients with severe HFrEF, with at least one marker for advanced HF, prescription and uptitration of GDMT remained limited. A significant proportion of patients were undertreated due to unknown reasons suggesting a potential role of clinical inertia either by the prescribing healthcare professional or by the patient. Treatment with BB and ACEi/ARB/ARNI was associated with lower mortality/morbidity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsStroke VolumeRegistriesAdrenergic beta-AntagonistsMineralocorticoid Receptor Antagonists

Stichwörter der Autor:innen

Advanced heart failureEvidence‐based medical therapyGuideline‐directed medical therapyHeart failure with reduced ejection fractionPrescriptionPrognosisSevere heart failure

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAdrenergic beta-AntagonistsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
  • Division of Cardiology, Department of Medicine, Karolinska Institutet, and Heart and Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.
  • Humanitas Research Hospital IRCCS, Rozzano, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
  • Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
  • Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ORCID-Profile: Marco Metra

Zitieren

APA

Tomasoni, D., Pagnesi, M., Colombo, G., Chiarito, M., Stolfo, D., Baldetti, L., Lombardi, C. M., Adamo, M., Maggi, G., Inciardi, R. M., Loiacono, F., Maccallini, M., Villaschi, A., Gasparini, G., Montella, M., Contessi, S., Cocianni, D., Perotto, M., Barone, G., …, & Metra, M. (2024). Guideline-Directed Medical Therapy in Severe Heart Failure with Reduced Ejection Fraction: An Analysis from the HELP-HF Registry. European Journal of Heart Failure, 26(2), 327-337. https://doi.org/10.1002/ejhf.3081

Vancouver

Tomasoni D, Pagnesi M, Colombo G, Chiarito M, Stolfo D, Baldetti L, et al. Guideline-Directed Medical Therapy in Severe Heart Failure with Reduced Ejection Fraction: An Analysis from the HELP-HF Registry. European Journal of Heart Failure. 2024;26(2):327-337. doi:10.1002/ejhf.3081

BibTeX
@article{Tomasoni2024,
  author = {Tomasoni, Daniela and Pagnesi, Matteo and Colombo, Giada and Chiarito, Mauro and Stolfo, Davide and Baldetti, Luca and Lombardi, Carlo Mario and Adamo, Marianna and Maggi, Giuseppe and Inciardi, Riccardo Maria and Loiacono, Ferdinando and Maccallini, Marta and Villaschi, Alessandro and Gasparini, Gaia and Montella, Marco and Contessi, Stefano and Cocianni, Daniele and Perotto, Maria and Barone, Giuseppe and Merlo, Marco and Cappelletti, Alberto Maria and Rosano, Giuseppe and Sinagra, Gianfranco and Pini, Daniela and Savarese, Gianluigi and Metra, Marco},
  title = {Guideline-Directed Medical Therapy in Severe Heart Failure with Reduced Ejection Fraction: An Analysis from the HELP-HF Registry},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {2},
  pages = {327--337},
  doi = {10.1002/ejhf.3081}
}
Kostenlos starten →